Navigation Links
DiObex and Camurus Sign License Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology
Date:3/18/2008

Development program for prevention of insulin-induced hypoglycemia in

diabetes

SAN FRANCISCO and LUND, Sweden, March 18 /PRNewswire/ -- DiObex and Camurus announced today that they have signed a license agreement to develop DIO-901(very low dose glucagon) in the Camurus drug delivery technology, FluidCrystal(R). The development candidate is an extended release formulation of low dose glucagon for the prevention of insulin-induced hypoglycemia in patients with diabetes.

"Intensive glycemic control is beneficial for patients with diabetes, but it increases their risk of hypoglycemia, which can lead to a spectrum of problems ranging from reduced quality of life to coma and death," said David Cory, DiObex CEO. "This license agreement and development program reflects our commitment to deliver an extended release form of low dose glucagon to the market for the prevention of insulin-induced hypoglycemia."

There is no product approved for the prevention of insulin-induced hypoglycemia in patients with diabetes. DiObex has successfully completed three Phase 1 proof-of-principle studies using very low dose glucagon infusions in type 1 diabetic patients. DIO-901 has received Fast Track status from the FDA for this program. The DIO-901 FluidCrystal(R) extended release formulation is scheduled to enter human clinical trials in the second half of 2008.

"We are very pleased to enter into this license agreement with DiObex and have great hope for the development of DIO-901. The extended release version of DIO-901 using our FluidCrystal(R) delivery technology has the potential to fulfill an important medical need in the treatment of diabetes," said Fredrik Tiberg, President and CEO of Camurus AB.

Terms of the agreement include an undisclosed signing fee, development milestones, future royalties on product sales and a share of any potential DiObex sublicensing revenues.

About DiObex

DiObex, Inc
'/>"/>

SOURCE DiObex, Inc.; Camurus AB
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. DiObex Inc. to Present at BIO Mid-America Venture Forum
2. DiObex, Inc. to Present at Merrill Lynch Global Healthcare Conference
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
5. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
6. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
7. Pharsight Achieves First License Sale for Public-Source Database
8. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
9. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
10. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...s., Sept. 5 /- Men living in Western,...h an enlarged prostate,now have the option of out-...biolitec, Inc. is pleased to announce that a netwo...s breakthrough LIFE(TM) (Laser Induced,Flow Enhanc...asia (BPH),that quickly and gently eliminates swol...
(Date:9/5/2008)...Regulatory Strategy for Belinostat in PTCL, COPEN... -- TopoTarget,A/S (OMX: TOPO) announced that a po...l Protocol Assessment (SPA) for a phase III trial ...a). This pivotal trial is to enrol,approximately 1...st Track,designation was granted for the developme...
(Date:9/5/2008).... 5 /- BioSpecifics,Technol...aceutical company,developing first in class collag...signed an agreement to significantly improve the d...s for Peyronie,s disease by buying down its,future..., BioSpecifics has modified its previously announ...
(Date:9/4/2008).... 4 /- Hologic, Inc.,(Nasda...Financial Officer,will be presenting at the Morga...eing held September 9, 2008, at the Grand Hyatt Ho...ted to listen to a live audio webcast of,Hologic,s...08, at 1:35 PM.,Eastern Time on the investor sect...
Breaking Biology Technology:Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon 2Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL 2Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL 3Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL 4Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL 5BioSpecifics Technologies Corp. Buys Down Royalties for Peyronie's Disease 2Hologic to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2
...d, Wis. - Determining how technology can help dri... an honest assessment of what doesn,t make sense...cal research institution in its backyard, it simpl...t spot," even if free land and tax incentives are ...g Wisconsin, scrambling to find the right niche wi...
... Wis. - For future generations of Native American...ld lead through some high-tech corridors. , ,An ef... adopting a more aggressive investment strategy, o...ology industry and the state economy. , ,After inv... and an IT firmthe Forest County Potawatomi Commu...
...is. - Following the announcement of increased qua... of rich-media technology, once again projected ca... with full year profitability projected for 2007. ...Minor released upbeat results for Sonic Foundry,s ...ilizing the company,s synchronized web presentatio...
..., Wis. - With its Investor Day program scheduled ...ews to spread. , ,The Brookfield-based global pro...es has reported stronger earnings for the second q... percentage increase in total revenues during the ... for the quarter increased 10 percent to $1.09 bil...
Other Biology Technology:Technology in the Northwoods 2Technology in the Northwoods 3Potawatomis to ramp up their investing 2Potawatomis to ramp up their investing 3Sonic closer to turning profit corner 2Sonic closer to turning profit corner 3Sonic closer to turning profit corner 4Fiserv reports stronger earnings and revenues 2Fiserv reports stronger earnings and revenues 3
(Date:9/4/2008)...ing researchers at the HudsonAlpha Institute and S...a number of other organizations, today publishes a...e brain cancer glioblastoma. These results are the...h network, a collaborative effort funded by the Na...ome Research Institute of the National Institutes ...
(Date:9/4/2008)...logy company have joined forces to develop a world... to predict premature birth with greater accuracy....Newcastle and Symbion Pathology are combining,exp...ogy to develop a computer program to predict,wome...-term births occur in Australia each year. Prematu...
(Date:9/4/2008)...ext great leap in medicine. In the future, new tis...heart, or new cells take the place of damaged cell...embryonic sources, which opens difficult ethical a...been looking to adult human stem cells, culled fro...ing cultivated from various tissues in the body &#...
(Date:9/4/2008)...of many serious diseases remain a mystery? In con...ity of California, San Diego School of Medicine ha...ivisible unit of life, the cell, which may provide...disciplines, Jamey Marth, Ph.D., UC San Diego Prof...tigator with the Howard Hughes Medical Institute, ...
Breaking Biology News(10 mins):Collaboration between researchers yields more comprehensive portrait of brain cancer 2World-first to predict premature births 2Tel Aviv University researchers create new stem cell screening tool 2Do 68 molecules hold the key to understanding disease? 2Money Matters 25459 3/ 1Stater Bros Raises 24200 000 for the Leukemia 26 Lymphoma Society 25457 1Stater Bros Raises 24200 000 for the Leukemia 26 Lymphoma Society 25457 2Older Adults Reluctant to Question Surgical Treatment 25455 1Older Adults Reluctant to Question Surgical Treatment 25455 2Light receptors in eye play key role in setting biological clock study shows 4480 1Light receptors in eye play key role in setting biological clock study shows 4480 2
...Consejo Superior de Investigaciones Científicas (C...of proteins in plant cells, a discovery that will ...ies. Amongst other applications, these can be used...ed, will be able to immunise against diseases. Mor... of protein-manufacturing plants of great interest...
...ice of killing wild badgers to prevent tuberculosi... newstudy led by Rosie Woodroffe, an ecologist at ...f Britain,s Independent Scientific Group on Cattle...otectionists have battled for 30 years over the me...is, a disease which can occasionally be transmitte...
...t on embryonic stem cells also has been found on t...ry that may help researchers isolate and purify ad...healing, tendon repair and cartilage regeneration,...ort. , The molecule, called SSEA-4, was found on t...at give rise to fat, cartilage and bone. These so-...
...f scientists has published the first two genome se...s called Phytophthora--a name that literally means...ngus-like Phytophthora (pronounced "fy-TOFF-thor-u...st the agriculture, forestry and nursery industrie...n though Phytophthora are similar to fungi, most f...
Other Biology News:Vaccine-producing 'plant-factories' 2British cattle give TB to badgers, finds UC Davis expert 2Molecular 'marker' on stem cells aids research, perhaps therapies 2Genome info from 'plant destroyers' could save trees, beans and chocolate 2
BD FACSAria Cell Sorting System from BD Biosciences - Immunocytometry Systems
...tial for hunting and analyzing the rare transcript...quencing projects, microarrays, functional screeni...ed for normalization of cDNA enriched with full-le...g. While most normalization methods are not well s...
Peptide-affinity Purified Polyclonal Antibody to ICEBERG Peptide with sequence EEDPQLASKMGLH, from C Terminus of the protein sequence according to NP_067546
Purified anti-Fanconi anemia D2-Phosphorylated (Ser222)
Biology Products: